See what makes our pediatric oncology and hematology research stand out at Johns Hopkins All Children’s Cancer & Blood Disorders Institute.
New research is a crucial part of what makes our pediatric oncology and hematology teams great. By exploring innovative treatments, documenting and analyzing data, and sharing our findings, we help advance the care available for children everywhere.
Our current cancer and blood disorders research includes:
More than 100 active research studies in hematology-oncology, with phase I trials and phase II trials that include investigator/initiated studies.
A $717,000 National Cancer Institute innovation grant in 2017 to study the use of saliva, instead of plasma, to monitor for potential chemotherapy toxicity. This less invasive way to track the presence of chemotherapy agents in the bloodstream could help us understand short- and long-term side effects of chemotherapy in children without the need for continuous blood draws. The study unites investigators in St. Petersburg, Fla., and Baltimore, Md., working together to advance the field of biorepository science.
A coordinating center for the Prospective Multicenter Evaluation of Duration of Therapy for Thrombosis in Children (the Kids-DOTT Trial), a randomized, controlled and blinded phase III clinical trial that includes nearly 40 major pediatric centers worldwide.
The only pediatric biorepository in Florida is based here and part of the Johns Hopkins All Children's Molecular Determinants Core. A biorepository allows storage of samples for future studies and expanded research opportunities.